Open AccessMultimodality assessments of wild‐type transthyretin cardiac amyloidosis with no ventricular hypertrophy
Author(s) -
Iwaya Takuma,
Okada Atsushi,
Tateishi Emi,
Ohta Yasutoshi,
Morita Yoshiaki,
OhtaOgo Keiko,
Izumi Chisato
Publication year - 2023
Publication title -
esc heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.787
H-Index - 25
ISSN - 2055-5822
DOI - 10.1002/ehf2.14220
Subject(s) - medicine , cardiac amyloidosis , transthyretin , muscle hypertrophy , heart failure , cardiology , stenosis , amyloidosis , scintigraphy , left ventricular hypertrophy , cardiac hypertrophy , radiology , blood pressure
While patients with transthyretin cardiac amyloidosis (ATTR‐CA) typically present with concentric or asymmetric hypertrophy, a small percentage of ATTR‐CA is known to present with ‘atypical’ cardiac morphologies such as eccentric hypertrophy or even no hypertrophy. However, detailed report of multimodality assessments of ATTR‐CA with no ventricular hypertrophy is lacking. Herein, we report detailed multimodality assessments of an 81‐year‐old Japanese woman with heart failure and history of carpal tunnel syndrome and lumbar canal stenosis, presenting no ventricular hypertrophy and negative 99m technetium‐pyrophosphate scintigraphy, who was eventually diagnosed as having wild‐type ATTR‐CA. Our case highlights the role of multimodality assessments for early diagnosis of ATTR‐CA in patients with atypical cardiac morphologies and also emphasizes the limitations of bone scintigraphy and the importance of considering ATTR‐CA in patients with non‐cardiac manifestations of ATTR amyloidosis.